Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy (MERIT-NHL)

University Hospital, Saarland

Status: Unknown

Conditions: Follicular Lymphoma

Study type: Observational

Funder types: Other

Identifiers

NCT01151358

MERIT-NHL

Details and patient eligibility

About

MERIT-NHL as an addendum to the International Registry of Radioimmunotherapy (RIT registry) pooling clinical data of patients who suffered from a non-Hodgkin´s lymphoma also includes the documentation of the respective FDG-PET and CT-image files in an online archive.

Based on these documented clinical and imaging data, the MERIT study group centrally performs an intra- as well as interindividual evaluation of follicular CD20+ lymphoma lesions before and after radioimmunotherapy. According to this, the aim of the MERIT-NHL study is to prospectively identify yet unknown patient- and lesion specific prognostic factors predicting patient´s outcome in line with the therapeutic modality radioimmunotherapy.

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• standard radioimmunotherapy with 90-yttrium-labeled anti-CD20-antibodies in treatment of relapsed and/or refractory follicular NHL or partial remission after induction chemotherapy
• finding of at least one image-guided measurable lymphoma lesion
• existence of FDG-PET- and CT-image data of at most 8 weeks before treatment
• signed patient´s agreement for RIT registry and MERIT-NHL

Exclusion criteria

• other therapy modalities than standard radioimmunotherapy (e.g. consolidation)
• solely CNS-lymphoma or primary effusion lymphoma